Authors
Latest:
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic OncologyAbdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
Latest:
Dr Melstrom on Challenges Implementing Widespread Molecular Testing in GI CancerLaleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.
Latest:
Dr. George on the Risk of Cardiotoxicity with Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast CancerMridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.
Latest:
FDA Approvals of Immunotherapy in Gynecology OncologyIn this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Latest:
Treatment Selection in mNSCLC without Actionable Genetic AlterationsHossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.
Latest:
Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple MyelomaFenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Latest:
Future Perspectives on the Treatment Landscape for CLLA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Latest:
Dr Karam on Key Kidney Cancer Takeaways From the 2023 IKCSJose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.
Latest:
Dr Park on the Rationale for the SYMPHONY-1 Trial in Relapsed/Refractory FLSteven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.
Latest:
Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ TransplantMichael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.
Latest:
Unmet Needs in SM TreatmentThe panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
Latest:
Dr. Ligon on Delivering CAR T-cell Therapy via Mediport Lines in Pediatric B-Cell MalignanciesJohn Ligon, MD, discusses findings from a study investigating the use of mediports to deliver CAR T-cell therapy in patients at Pediatric Real-World CAR Consortium medical centers.
Latest:
Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced MelanomaInderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AMLBradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Future Perspectives in the Treatment of Polycythemia VeraJohn Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.
Latest:
Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple MyelomaDickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.
Latest:
Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung CancerVlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr Blackwood on the Significance of Early Breast Cancer ScreeningsM. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.
Latest:
Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular CancerJennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.
Latest:
UChicago Medicine Among the First to Offer Histotripsy for Liver TumorsThe University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.
Latest:
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsAmanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Latest:
Future of MFExperts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.
Latest:
Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLCCatherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.
Latest:
Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast CancerMeghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract CancerMojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.
Latest:
Dr Massarelli on the Current SCLC Treatment ArmamentariumErminia Massarelli, MD, PhD, MS, discusses clinical gaps in lung cancer care that were highlighted at the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of molecular testing in patients with small cell lung cancer and collaborations between health care networks in this treatment arena.
Latest:
Dr Chudgar on Defining Resectability in NSCLCNeel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.
